{"transactions":[{"id":1507598,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-22T00:15:25.000Z","date":"2024-05-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":268,"price":16.13,"value":4322.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants."}],"balance_after":40510,"source":{"system":"sec-edgar","filing":"0000899140-24-000628","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914024000628/form4.xml","form_type":"4"}},{"id":1589827,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Non-statutory Stock Option","published_at":"2024-03-08T00:02:35.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":27338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Ronsheim's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a \"change in control\" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Ronsheim experiences a termination of employment by the Innoviva, Inc. without \"cause\" or by Dr. Ronsheim for \"good reason\" (each as defined in Dr. Ronsheim's employment agreement) within 24 months following a \"change in control,\" subject to an effective release of claims."}],"balance_after":120438,"derivative":{"exercise_price":14.88,"exercise_date":"2025-02-20","expiration_date":"2034-03-05","underlying":"Common Stock","underlying_shares":27338},"source":{"system":"sec-edgar","filing":"0001104659-24-032002","document":"tm248180-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924032002/tm248180-2_4seq1.xml","form_type":"4"}},{"id":1589826,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-03-08T00:02:35.000Z","date":"2024-03-05","kind":"grant","planned":false,"acquired":true,"shares":12768,"price":14.88,"value":189987.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person was granted a one time-based restricted stock unit (\"RSU\"). Twenty-five percent of the shares subject to the RSU shall vest on February 20, 2025, 6.25% on May 20, 2025, and an additional 6.25% on the final day of each 3-month period thereafter, provided the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The grant was approved by the Compensation Committee of the Board of Directors of the Company."}],"balance_after":40778,"source":{"system":"sec-edgar","filing":"0001104659-24-032002","document":"tm248180-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924032002/tm248180-2_4seq1.xml","form_type":"4"}},{"id":1626164,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-02-23T02:31:05.000Z","date":"2024-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":807,"price":15.8,"value":12750.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants."}],"balance_after":28010,"source":{"system":"sec-edgar","filing":"0001104659-24-026716","document":"tm246891-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465924026716/tm246891-2_4seq1.xml","form_type":"4"}},{"id":1674540,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Nonqualified Stock Option","published_at":"2024-01-23T02:16:54.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the options will vest on February 20, 2025 and the balance will vest in twelve (12) substantially equal installments thereafter on each three (3) month anniversary of the initial vesting date, in each case, subject to Dr. Ronsheim's continuous service through the applicable vesting date, with accelerated vesting (i) in the event of a \"change in control\" (as defined in the Issuer's 2012 Equity Incentive Plan) in which the options are not assumed or replaced, or (ii) in the event that Dr. Ronsheim experiences a termination of employment by the Innoviva, Inc. without \"cause\" or by Dr. Ronsheim for \"good reason\" (each as defined in Dr. Ronsheim's employment agreement) within 24 months following a \"change in control,\" subject to an effective release of claims."}],"balance_after":93100,"derivative":{"exercise_price":16.05,"exercise_date":"2025-02-20","expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000899140-24-000058","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914024000058/form4.xml","form_type":"4"}},{"id":1674539,"issuer":{"id":4679,"kind":"organization","name":"Innoviva, Inc."},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-23T02:16:54.000Z","date":"2024-01-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":1600,"price":16.05,"value":25680.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were withheld by the Issuer to satisfy income tax withholding obligations associated with the quarterly vesting of previously granted employee equity grants."}],"balance_after":28817,"source":{"system":"sec-edgar","filing":"0000899140-24-000058","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080014/000089914024000058/form4.xml","form_type":"4"}},{"id":2209063,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Pharma Sciences & MFG"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-11T16:09:04.000Z","date":"2022-07-11","kind":"other","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":4.8,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-078801","document":"tm2220760-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922078801/tm2220760-9_4seq1.xml","form_type":"4"}},{"id":2209062,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Pharma Sciences & MFG"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-11T16:09:04.000Z","date":"2022-07-11","kind":"other","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":4.7,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-22-078801","document":"tm2220760-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922078801/tm2220760-9_4seq1.xml","form_type":"4"}},{"id":2209061,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Pharma Sciences & MFG"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-11T16:09:04.000Z","date":"2022-07-11","kind":"other","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":2.86,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-078801","document":"tm2220760-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922078801/tm2220760-9_4seq1.xml","form_type":"4"}},{"id":2209060,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Pharma Sciences & MFG"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-11T16:09:04.000Z","date":"2022-07-11","kind":"other","acquired":false,"shares":33333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each vested and unvested Issuer stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable. All stock options held by the reporting person were cancelled in the Merger as the exercise price of each such option was greater than the Offer Price."}],"balance_after":0,"derivative":{"exercise_price":2.44,"underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001104659-22-078801","document":"tm2220760-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922078801/tm2220760-9_4seq1.xml","form_type":"4"}},{"id":2209059,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Pharma Sciences & MFG"}}],"security":"Common Stock","published_at":"2022-07-11T16:09:04.000Z","date":"2022-07-11","kind":"disposition_to_issuer","acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the \"Merger\") became effective (the \"Effective Time\") was cancelled and converted into the right to receive a right to receive a number of RSUs in respect of shares of Innoviva common stock equal to (x) the number of Shares subject to Issuer RSUs immediately prior to the Effective Time, multiplied by (y) the Offer Price, divided by (z) the per share volume-weighted average price of Innoviva common stock for the 10 business days prior to the closing date of the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the \"Merger\") became effective (the \"Effective Time\") was cancelled and converted into the right to receive a right to receive a number of RSUs in respect of shares of Innoviva common stock equal to (x) the number of Shares subject to Issuer RSUs immediately prior to the Effective Time, multiplied by (y) the Offer Price, divided by (z) the per share volume-weighted average price of Innoviva common stock for the 10 business days prior to the closing date of the Merger."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-078801","document":"tm2220760-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922078801/tm2220760-9_4seq1.xml","form_type":"4"}},{"id":2209058,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief of Pharma Sciences & MFG"}}],"security":"Common Stock","published_at":"2022-07-11T16:09:04.000Z","date":"2022-07-07","kind":"other","acquired":false,"shares":17572,"price":2.2,"value":38658.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of to Innoviva Merger Sub, Inc. (\"Merger Sub\"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. (\"Innoviva\"), and Merger Sub (the \"Merger Agreement\"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the \"Offer Price\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Disposed of to Innoviva Merger Sub, Inc. (\"Merger Sub\"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. (\"Innoviva\"), and Merger Sub (the \"Merger Agreement\"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the \"Offer Price\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-22-078801","document":"tm2220760-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922078801/tm2220760-9_4seq1.xml","form_type":"4"}},{"id":2393839,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-15T16:04:44.000Z","date":"2021-07-16","kind":"grant","acquired":true,"shares":33333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 40,000 shares of issuer's common stock granted to the Reporting Person on September 17, 2019. In exchange, the Reporting Person received a replacement option for 33,333 shares of issuer's common stock, having an exercise price of $2.44 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Sixty-nine percent (69%) of this award will vest on July 16, 2022, and one-fifteenth of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date."}],"balance_after":33333,"derivative":{"exercise_price":2.44,"expiration_date":"2031-07-15","underlying":"Common Stock","underlying_shares":33333},"source":{"system":"sec-edgar","filing":"0001104659-22-023783","document":"tm226724-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922023783/tm226724-9_4seq1.xml","form_type":"4"}},{"id":2393838,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-02-15T16:04:44.000Z","date":"2021-07-16","kind":"disposition_to_issuer","acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 40,000 shares of issuer's common stock granted to the Reporting Person on September 17, 2019. In exchange, the Reporting Person received a replacement option for 33,333 shares of issuer's common stock, having an exercise price of $2.44 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option provided for vesting as follows: Twenty-five percent (25%) of the option award will vest on September 17, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date."}],"balance_after":0,"derivative":{"exercise_price":5.12,"expiration_date":"2029-09-16","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001104659-22-023783","document":"tm226724-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922023783/tm226724-9_4seq1.xml","form_type":"4"}},{"id":2431746,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-01-19T16:04:31.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This award vests over four years with twenty-five percent of the award vesting on each anniversary of the date of grant, subject to the reporting person's continued employment with the Company."}],"balance_after":167572,"source":{"system":"sec-edgar","filing":"0001104659-22-005425","document":"tm223320-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465922005425/tm223320-10_4seq1.xml","form_type":"4"}},{"id":2525581,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief, Pharma Sciences & MFG."}}],"security":"Common Stock","published_at":"2021-11-03T16:05:56.000Z","date":"2021-11-02","kind":"tax_withholding","acquired":false,"shares":3669,"price":2.94,"value":10786.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares withheld solely for purposes of the payment of taxes arising in connection with the vesting of restricted stock units on November 2, 2021. The number of shares withheld was determined based on the closing price on the last trading day prior to vesting, which was November 1, 2021."}],"balance_after":42572,"source":{"system":"sec-edgar","filing":"0001104659-21-133635","document":"tm2131811-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465921133635/tm2131811-3_4seq1.xml","form_type":"4"}},{"id":2537893,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-20T16:05:37.000Z","date":"2021-10-19","kind":"sale","acquired":false,"shares":3759,"price":3.19,"value":11991.21,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold solely for purposes of the payment of taxes arising in connection with the vesting of restricted stock units on October 19, 2021. The number of shares sold was determined based on the closing price on the last trading day prior to vesting, which was October 18, 2021."}],"balance_after":46241,"source":{"system":"sec-edgar","filing":"0001104659-21-128054","document":"tm2130633-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465921128054/tm2130633-1_4.xml","form_type":"4"}},{"id":2537892,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-10-20T16:05:37.000Z","date":"2021-10-19","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Acquired as a result of the satisfaction of the performance criteria of the underlying award as of the date stated. Fifty percent of this award vested on such date and the remaining fifty percent will vest on the first anniversary of such date, subject to the reporting person's continued employment with the Company."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001104659-21-128054","document":"tm2130633-1_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465921128054/tm2130633-1_4.xml","form_type":"4"}},{"id":2903829,"issuer":{"id":16036,"kind":"organization","name":"Entasis Therapeutics Holdings Inc.","symbol":"ETTX"},"owners":[{"id":90782,"kind":"person","name":"Ronsheim Matthew","position":1,"cik":"0001824386","reported_name":"Ronsheim Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-19T16:09:00.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001104659-21-005318","document":"tm213545-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724344/000110465921005318/tm213545-5_4seq1.xml","form_type":"4"}}]}